CDT Equity advances patent strategy for AZ-acquired myeloperoxidase inhibitor for male infertility

Edited by Robert McTiernan··2 min read

CDT Equity Inc. (Nasdaq: CDT), headquartered in Naples, Florida, has advanced AZD5904, a selective myeloperoxidase (MPO) inhibitor originally licensed from AstraZeneca, into the Patent Cooperation Treaty (PCT) phase, broadening the international intellectual property footprint of the asset ahead of formal out-licensing discussions. The AZD5904 patent progression reflects a strategy to de-risk the asset through IP consolidation before engaging pharmaceutical partners for later-stage development in idiopathic male infertility.

The AZD5904 patent: composition, mechanism, and indication scope

CDT holds two distinct patent types covering AZD5904: a composition of matter patent and a method of use patent, both directed at the indication of idiopathic male infertility. The PCT filing extends the potential scope of that protection across multiple international jurisdictions, though the company has not disclosed which specific national phase entries are being pursued or the remaining term of the underlying patents.

The biological rationale for the AZD5904 patent in male infertility centers on the role of MPO-driven oxidative stress in the reproductive tract. MPO is an enzyme expressed by neutrophils and other immune cells that catalyzes the production of hypochlorous acid and other reactive oxygen species. In seminal plasma, elevated MPO activity has been associated with oxidative damage to sperm DNA and membranes, contributing to reduced motility and fertilization capacity in men with idiopathic infertility. AZD5904 is designed to inhibit MPO selectively, with the aim of reducing that oxidative burden on sperm. Published in vitro work, including a 2020 study by Campbell et al. in Human Reproduction (DOI: 10.1093/humrep/deaa328), reported that AZD5904 enhanced aspects of human sperm function under laboratory conditions, providing a mechanistic basis for the composition and method claims.

The company has also identified signals for AZD5904 in oncology-associated infertility, a secondary indication that may reflect the broader relevance of MPO inhibition in inflammatory or treatment-related reproductive impairment. However, no clinical data in that context have been disclosed.

The AllSci BriefSystematic R&D and deal news. Daily.

Development history and current stage

The AZD5904 clinical development record, as disclosed by CDT, consists of five Phase I studies in which a total of 181 subjects were dosed. The company states that no overtly drug-related adverse events were identified across that dataset, characterizing the safety profile as favorable. These Phase I studies were not conducted by CDT in the infertility indication; they reflect earlier clinical work undertaken during the asset’s prior development history under AstraZeneca, from which CDT licensed the compound. Specific indications, endpoints, and trial registry identifiers for those five studies have not been publicly disclosed by CDT.

The current idiopathic male infertility program remains at a preclinical stage. CDT is positioning the existing Phase I safety package as clinical validation of tolerability, which it argues reduces development risk for prospective partners.

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/